iBio(IBIO) - 2024 Q4 - Annual Results

Exhibit 99.1 iBio Reports Fiscal Year 2024 Financial Results and Provides Corporate Update San Diego, California / September 20, 2024 / (GLOBE NEWSWIRE) / iBio, Inc. (NYSEA:IBIO), an AI-driven innovator of precision antibody immunotherapies, today announced its financial results for the fiscal year ended June 30, 2024, and provided a corporate update. "Our fiscal year 2024 was a transformational year for iBio, as we've solidified our business and financial position as a next-generation antibody company with ...